

tance and necessitates a higher electrical charge to defibrillate the ventricle. PRP can be used to treat the fibrosis either prior to, during, or after the placement of an ICD. PRP can also be used in the treatment of patients undergoing heart transplant or valve surgery to improve rhythm or function.

A patient is diagnosed with ischemic cardiomyopathy and his doctors recommend that he have an ICD. Prior to ICD placement, the cardiac tissue in the area where the leads of the ICD are to be placed is injected or infused with PRP. Local fibrosis is reduced thus enabling the ICD to operate at a lower voltage when activated. This extends the battery life of the ICD.

While methods, devices, and kits have been described in some detail here by way of illustration and example, such illustration and example may be for purposes of clarity of understanding only. It will be readily apparent to those of ordinary skill in the art in light of the teachings herein that certain changes and modifications may be made thereto without departing from the spirit and scope of the appended claims.

What is claimed is:

1. A method for treating a cardiac conduction abnormality, comprising:
  - identifying a cardiac conduction abnormality in a patient; and
  - delivering a platelet rich plasma composition to the patient, wherein the platelet rich plasma composition is in an inhalable form.
2. The method of claim 1, wherein the conduction abnormality is a cardiac arrhythmia.

3. The method of claim 1, wherein the patient has a negative cardiac enzyme elevation.

4. The method of claim 1, further comprising monitoring the conduction abnormality after delivering the platelet rich plasma composition.

5. The method of claim 1, wherein the conduction abnormality is selected from the group consisting of bradycardia, tachycardia, ventricular tachycardia, and ventricular fibrillation.

6. The method of claim 1, wherein the conduction abnormality is chronic, acute or episodic.

7. The method of claim 1, wherein determining a cardiac conduction abnormality exists comprises using an electrocardiogram, Holter monitor or a cardiac event monitor.

8. The method of claim 1, wherein the platelet rich plasma composition is prepared from whole blood of the patient.

9. The method of claim 1, wherein the platelet rich plasma composition is buffered to a physiological pH, and wherein the physiological pH is between about 7.3 and about 7.5.

10. The method of claim 1, wherein the inhalable form is an inhalable powder.

11. The method of claim 1, wherein the treatment further comprises administering an anti-arrhythmic agent selected from the group consisting of a sodium channel blocker, a beta blocker, a potassium channel blocker, and a calcium channel blocker.

12. The method of claim 1, wherein the inhalable form is delivered with a nebulizer or inhaler.

13. The method of claim 1, wherein the conduction abnormality is due at least in part to reperfusion therapy.

\* \* \* \* \*